GEN Exclusives

More »

GEN News Highlights

More »
Mar 25, 2010

Scientists Identify Gene Abnormality that Is Predictive of Breast Cancer Response to Anthracyclines

  • An international research team claims that the CEP17 gene on chromosome 17 represents a promising biomarker for predicting whether breast cancer patients will respond to anthracycline therapy. The research is being presented at the “Seventh European Breast Cancer Conference” being held in Barcelona.

    Led by John Bartlett, Ph.D., professor of molecular pathology at the University of Edinburgh, the group found that an abnormality in the CEP17 gene is predictive of a worse outcome for breast cancer patients but also indicates that tumors in these patients will respond to anthracycline therapy.

    The results emerged from the team’s meta-analysis of four breast cancer trials that included nearly 3,000 patients. Their analysis found that after adjusting for additional factors, patients with the CEP17 abnormality who were treated using anthracyclines were two third more likely to survive as well as survive without cancer recurrence than those who didn’t receive anthracyclines.

    Dr. Bartlett suggests that if the results can be confirmed, it may indicate that that “only those patients with CEP17 tumors should receive anthracyclines, thereby enabling other patients who do not have the CEP17 abnormality to avoid a toxic treatment that will not be effective.”

    Although CEP17 is located on the same chromosome as the known breast cancer-related genes, HER2 and TOP2A, the new research could find no association between them. “We need to understand what CEP17 is telling us about the behavior of breast cancer cells,” Dr. Bartlett admits. “It works as a biomarker for predicting response to anthracyclines, but we don’t know why it works. So our next step is to discover this and to try to make the cancers that don’t have the marker behave like the ones that do, so that they will respond to anthracyclines.”

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »